VJHemOnc Podcast Updates on the diagnosis, risk stratification and treatment of lower-risk MDS
Oct 6, 2023
Sanam Loghavi, medical doctor from The University of Texas MD Anderson Cancer Center, discusses updates on the diagnosis, risk stratification, and treatment of lower-risk MDS. Topics include the challenges in managing LR-MDS, the importance of accurate diagnosis and risk stratification using the IPSS-M model, FDA approval of Luspattersept frontline therapy, constructing pathology reports for optimal patient care, and incorporating various diagnostic tools for diagnosing LR-MDS.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 3min
Testing Methods and Risk Stratification in Lower-Risk MDS
02:52 • 6min
FDA Approval of Luspattersept for Frontline Therapy in Lower-Risk MDS
08:28 • 6min
Constructing Pathology Reports for Optimal Patient Care
13:59 • 2min
Incorporating all available information and pathology tricks for diagnosing lower-risk MDS
15:50 • 3min